HUMIRA® (adalimumab) - A Biologic Medication
What is the most important information I should know about HUMIRA? You should discuss the potential benefits and risks of HUMIRA with your doctor. HUMIRA is a TNF blocker medicine that can lower the ability of your immune system to fight infections.
HUMIRA should be discontinued if a patient develops a serious infection or sepsis.
HUMIRA is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn’s disease who have had an inadequate...
HUMIRA® (adalimumab) | For Healthcare Professionals
HUMIRA is indicated for the treatment of rheumatology, dermatology, and gastroenterology indications. Review efficacy, safety data, and more.
Humira: Package Insert / Prescribing Information - Drugs.com
Humira package insert / prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions and pharmacology.
HUMIRA (adalimumab), Abbott Laboratories - Package Insert
2003年1月27日 · HUMIRAä (adalimumab) is supplied in glass vials and syringes as a preservative-free, sterile solution for subcutaneous administration. The following packaging configurations are available:...
What is the most important information I should know about HUMIRA? You should discuss the potential benefits and risks of HUMIRA with your doctor. HUMIRA is a TNF blocker medicine that can lower the ability of your immune system to fight infections. You …
Humira: Uses, Dosage, Side Effects, Warnings - Drugs.com
2024年3月15日 · Before or during treatment with Humira, tell your doctor if you have signs of infection such as fever, chills, aches, tiredness, cough, skin sores, diarrhea, or burning when you urinate. Before taking this medicine. You should not use Humira if you are allergic to adalimumab.
Humira (AbbVie Inc.): FDA Package Insert - MedLibrary.org
2024年2月1日 · Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before HUMIRA use and during therapy. Initiate treatment for latent TB prior to HUMIRA use.
Discontinue HUMIRA if a patient develops a serious infection or sepsis. Reported infections include: • Active tuberculosis (TB), including reactivation of latent TB.